New video from Crystec highlights mSAS technology

mSAS particle engineering versus conventional micronisation

The video is a visual demonstration of the advantages that Crystec’s mSAS (modified supercritical antisolvent) platform has compared with conventional technologies, and the impact that such processing can have on the ease of subsequent manufacturing, as well as product performance.


For more information on how mSAS can accelerate development and enhance the performance of medicines, please visit www.crystecpharma.com.

Companies